MCMeryem Can

Meryem Can

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Meryem Can has a total of 79 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Romatolojide Güncel Tedaviler

    by Duygu Kurtuluş, Ali Nail Demir, İsMail Uçar, Önay Gerçik, Hüseyin Ali Öztürk, Alper Yıldırım, Neslihan Gökçen, Zeynep Kaya, Meryem Can, Zübeyde Uğurlu, et al.

    Analjezikler, Non-Steroid Anti-İNFLAMATUAR İlaçlar ve Kortikosteroidler Duygu KURTULUŞ Biyolojik Olmayan Hastalık Modifiye Edici Antiromatizmal ilaçlar Ali Nail DEMİR Romatolojide Biyolojik Tedavi Ajanları İsmail UÇAR İmmunsupresifler ve Diğer İlaçlar Önay GERÇİK Romatolojide İntravenöz İmmünoglobulin Uygulamaları Hüseyin Ali ÖZTÜRKAlper YILDIRIM Romatolojide Plazmaferez Uygulamaları Alper YILDIRIM Erken Artrit ve Palindromik Romatizma: Güncel Tedavi Neslihan GÖKÇEN Romatoid Artrit: Güncel Tedavi Zeynep KAYA Meryem CAN Romatoid Artritte Ekstra-Artiküler Tutulum Tedavisi Zübeyde UĞURLU Atalay DOĞRU Tekrarlayıcı Seronegatif Pİtting Ödemli Simetrik Sinovit (R3SPE) Sendromu Tedavi Yönetimi Berkan ARMAĞAN Erişkin Başlangıçlı Still Hastalığına Güncel Yaklaşım Ahmet KOR Şükran ERTEN Enfeksiyöz Artritler: Bakteriyel Artritler, Lyme Artriti, Viral Artritler, Mikobakteriyel, Brucella, Fungal Ve Parazitik Artritler: Güncel Tedavi Fatma TUNCER KURU Ankilozan Spondilit ve Non-Radyografik Aksiyel Spondiloartrit: Güncel Tedavi Dilek SOLMAZ Periferik Spondiloartrit: Güncel Tedavi Fatih SARITAŞ Psöriatik Artrit: Güncel Tedavi Selda ÇELİK Enteropatik Artrit Tedavisi Mete PEKDİKER Reaktif Artrit: Güncel Tedavi Özgül SOYSAL GÜNDÜZ Jüvenil İdyopatik Artrit Tedavisinde Güncel Yaklaşımlar Kenan BARUT Elif KILIÇ KÖNT Özgür KASAPÇOPUR Sistemik Lupus Eritematozusda Güncel Tedavi Hamide Kart KÖSEOĞLU Sjögren Sendromunda Güncel Tedavi Yaklaşımları Pınar TALU ERTEN Antifosfolipid Sendromu Tedavisi Pınar AKYÜZ DAĞLI Ahmet OMMA Gebelikte Sistemik Lupus Eritematozus ve Antifosfolipid Antikor Sendromu: Güncel Tedavi Senar ŞAN Ayten YAZICI Kutanöz Lupus Eritematosus: Güncel Tedavisi Tuğba TEHÇİ Sistemik Skleroz Tedavisi Yasemin YALÇINKAYA Raynaud Fenomeninin Güncel Tedavisi Duygu TEMİZ KARADAĞ İdiopatik İnflamatuar Myopati Güncel Tedavi Figen TARHAN Anti-Sentetaz Sendromu Emel GÖNÜLLÜ Mix Konnektif Doku Hastalığında Güncel Tedavi İpek TÜRK Undiferansiye Bağ Dokusu Hastalığı ve Overlap Sendromlar Güncel Tedavi Derya KAŞKARİ Poliarteritis Nodosa Güncel Tedavisi Esra KAYACAN ERDOĞAN Dev Hücreli Arterit ve Polimyaljiya Romatika Tedavisi Vedat GERDAN Granülomatöz Polianjiitis’te Güncel Tedavi Özlem DOĞAN AĞBUGA Diğer Anca İlişkili Vaskülitlerde Güncel Tedavi Emrah KOÇ Takayasu Arteriti Güncel Tedavisi Sema KAYMAZ TAHRA Fatma ALİBAZ ÖNER Klinik Tutulumlara Göre Behçet Hastalığında Güncel Tedavi Yüksel MARAŞ Kawasaki Hastalığı Güncel Tedavi Rabia Miray KIŞLA EKİNCİ İmmun Kompleks Küçük Damar Vaskülitlerinde Güncel Tedavi Elif EDİBOĞLU Sarkoidoz: Güncel Tedavi Müge AYDIN TUFAN Relapsing Polikondrit Suade Özlem BADAK IgG4 İlişkili Hastalık: Güncel Tedavi Nazife Şule YAŞAR BİLGE Timuçin KAŞİFOĞLU Ailevi Akdeniz Ateşi: Güncel Tedavi Zeynep TOKER DİNÇER Serdal UĞURLU Henoch Schönlein Purpurası (HSP) Özge Altuğ GÜCENMEZ FMF Dışı Otoenflamatuar Hastalıklar: Güncel Tedavi Amra ADROVİÇ Mehmet YILDIZ Özgür KASAPÇOPUR Otoinflamatuar Hastalıklarda Aa Amiloidoz Güncel Tedavi Safiye BAKKALGerçek CAN Gut: Güncel Tedavi Gezmiş KİMYON CPPD Güncel Tedavi Fatih Necip ARICI Alper YILDIRIM Konnektif Doku Hastalığı İlişkili Pulmoner Arteriyel Hipertansiyon Tedavisi Alper SARI Romatolojik Hastalıklarda İnterstisyel Akciğer Hastalığı: Güncel Tedavi Zevcet YILMAZ Romatolojik Hastalıklarda Aşılama Mehmet Ali AŞIK Gebe, Emziren Ve Gebelik Planı Olan Romatoloji Hastalarında Paternal ve Maternal İlaç Kullanımı Sercan GÜCENMEZ

    • 2 December 2013
      • Vol. 32, S103-5

    An unusual case with vasculo-Behçet's disease: peripheral arterial aneurysm in an elderly woman.

    by Sibel Yilmaz-Oner, Meryem Can, Gulsen Ozen, Buge Oz, Feyyaz Baltacioglu, Hasan Tuzun, Haner Direskeneli

    Behçet's disease (BD) is a chronic, multi-systemic disorder that can affect all sizes of arteries and veins. Vascular involvement of BD is generally observed in young men and is an important cause of morbidity and mortality. Arterial lesions can appear as aneurysms, stenosis and occlusions in BD. We, here, present the case of a woman who developed a peripheral arterial aneurysm in her sixth decade, 20 years after disease onset. BD patients with aneurysms should be consulted at any age for pre- and post-operative assessment for immunosuppressive treatment to reduce recurrences, complications and disease activation.


  • Activity and damage in granulomatosis with polyangiitis

    by Ender G. Yegin, Meryem Can, Neslihan Yilmaz, Sibel Z. Aydin, Sule Yavuz, Serhan Tuglular, Haner Direskeneli

    Aim To retrospectively analyze disease activity and damage-associated factors in granulomatosis with polyangiitis (GPA) in Turkey. Method A retrospective analysis was carried out in 21 GPA patients. Assessments for activity were performed with the Birmingham Vasculitis Activity Score for GPA (BVAS/GPA) and for permanent organ damage by the Vasculitis Damage Index (VDI). Results Lower BVAS/GPA (P = 0.002), absence of renal involvement (P = 0.003) and higher creatinine clearence (P = 0.000) at diagnosis increased the likelihood of achieving remission at 6 weeks. Relapses were associated with high creatinine clearence (P = 0.021), low BVAS/GPA (P = 0.014), absence of renal involvement (P = 0.036) and proteinuria (< 0.5/24 h) (P = 0.013) at diagnosis, whereas achieving remission at 6 weeks (P = 0.012) was associated with absence of co-trimoxazole usage (P = 0.038) and less severe clinical subgroup (P = 0.034). Lower cumulative first 6 months of cyclophosphamide and methylprednisolone were associated with earlier (≤ 12 months) relapses (P = 0.048 and P = 0.083, respectively). Baseline damage (VDI ≥ 1) was associated with a delay in diagnosis (P = 0.032), presentation with milder clinical subgroups (P = 0.052) and low serum creatinine (P = 0.013). The increase in VDI in the first 12 months (early damage) constituted most (91%) of the total damage measured at the end of follow-up. Conclusions Despite high early remission rates, relapse represents a major problem in localized GPA in our study. Baseline damage was associated with longer diagnostic delay and lower baseline serum creatinine. The initial phase of the disease seems to be the most crucial period for mortality and accumulated damage.


  • Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: a single-centre experience

    by Meryem Can, Fatma Alibaz-Öner, Sibel Yılmaz-Öner, Pamir Atagündüz, Nevsun İnAnç, Haner Direskeneli

    Due to the possible risk of infusion reactions of rituximab (RTX), a slow infusion rate (total infusion time, 255 min) is suggested for rheumatological use. However, especially in oncology field, accelerated infusion of RTX is reported to be well tolerated and safe. The aim of our study was to evaluate whether accelerated infusion rates of RTX would similarly be safe and tolerable in rheumatoid arthritis (RA) patients and other off-label rheumatological indications. All patients treated with RTX for RA and other autoimmune diseases between May 2011 and January 2012 were recruited to the study. Each treatment course consisted of two RTX 1,000 mg infusions, 2 weeks apart. Total time of the infusion for the first cycle was 255 min. Second and subsequent infusions were administered over 120 min as follows: 0–30 min, 100 mg; 30–60 min, 200 mg; 60–90 min, 300 mg; and 90–120 min, 400 mg. The Clinical Trials Classification of Adverse Events (CTCAE) version 4.3 was used to categorise side effects. The study population comprised 68 patients [F/M, 59:9; mean age, 52.4 (10.6) years]: 60 with RA, 4 with systemic lupus erythematosus (SLE), 1 with non-Hodgkin’s lymphoma with SLE and 3 with vasculitis. A total of 77 fast infusions were administered. Eleven patients (16.2 %) had taken a fast infusion at the first course. A total of nine patients experienced at least one AE. Seven patients had a reaction on the first infusion (infusion-related reaction (IRR)), two patients on the second infusion and one patient on both infusions. When graded from 1 to 5 according to CTCAE v. 4.3, grade 1 IRRs were observed in a total of seven patients and grade 2 IRR in three patients. In this study of fast infusions, adverse events after RTX were mostly mild and seem to be well tolerated. Faster rituximab infusion times seem to be safe and might be incorporated into routine practice.


  • Conventional DMARD therapy (methotrexate‐sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: A real‐life experience

    by Meryem Can, Sibel Z. Aydın, Adil Niğdelioğlu, Pamir Atagündüz, Haner Direskeneli

    Aim: The effect of disease‐modifying antirheumatic drugs (DMARDs) in ankylosing spondylitis (AS) is still controversial. We aimed to evaluate the efficacy of sulphasalazine (SSZ) mono‐ or combination therapy with methotrexate (MTX) in AS patients naive to anti‐tumor necrosis factor alpha (TNFα) agents.Methods: Patients with AS (n = 87, male : female, 46 : 41) treated with SSZ (n = 61) or SSZ + MTX (n = 26) combination and a documented 6‐month follow‐up were evaluated retrospectively. Disease activity was assessed by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), C‐reactive protein and erythrocyte sedimentation rate. Requirement for anti‐TNFα therapy was assessed after 6 months.Results: Mean (SD) age was 43.0 (11.0) versus 40.2 (11.1) and disease duration was 11.0 (8.6) versus 8.2 (5.2) years, in the SSZ and SSZ + MTX groups, respectively. Initially, 59% (34/61) of the patients in SSZ monotherapy and 68% (17/26) in the combination arm had BASDAI > 4. At the end of the study, BASDAI scores decreased similarly in both groups (mono: 1.4 [–7–6] versus combination: 0.7 [–3–6] P = 0.2). BASDAI was > 4 in 32.8% (20/61) of patients in the SSZ monotherapy and in 44% (11/26) in the combination arm. Only 4 (6.6%) patients in the SSZ group and 2 (7.7%) in the ombination arm were switched to anti‐TNFα therapies.Discussion: A significant subset of our AS patients responded to SSZ mono or SSZ + MTX combination therapies at 6 months follow‐up. Using BASDAI, the requirement for biological therapies decreased by 21–24%. In AS patients, including those with axial involvement only, DMARD therapy may be a reasonable first alternative to anti‐TNFα therapy and may delay the switch to biologic agents.